Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Illumina, Inc. v. Natera, Inc.
Case Number:
3:18-cv-01662
See also:
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
May 13, 2020
Natera, Illumina Ink Deal To End Row Over DNA Testing IP
Illumina Inc. and Natera Inc. have agreed to drop dueling patent infringement claims over fetal DNA testing technology in California federal court and to firm up a licensing agreement, according to a newly submitted regulatory filing.
-
June 26, 2018
Natera Loses Bid To Toss Illumina DNA Patent Under Mayo
A California federal judge on Tuesday refused to toss Illumina Inc.'s patent infringement litigation against rival Natera Inc., finding that there was not enough evidence yet to show whether Illumina's fetal DNA testing technology covers the type of natural phenomenon that would be unpatentable under Mayo.
-
May 18, 2018
Illumina Can't Enforce Fetal DNA Testing Patent, Natera Says
Natera Inc. on Thursday asked a California federal court to free it from patent infringement litigation brought by competitor Illumina Inc., arguing the fetal DNA testing technology at issue isn't patent eligible because it covers naturally occurring phenomena.